Tanvex BioPharma Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Stephen Lam

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Does Tanvex BioPharma (TWSE:6541) Have A Healthy Balance Sheet?

Aug 07

Is Tanvex BioPharma (TPE:6541) Using Too Much Debt?

Mar 18

Are Institutions Heavily Invested In Tanvex BioPharma, Inc.'s (TPE:6541) Shares?

Jan 19

Does Tanvex BioPharma (TPE:6541) Have A Healthy Balance Sheet?

Nov 24

CEO

Stephen Lam

less than a year

Tenure

Mr. Stephen Lam is Chief Executive Officer of Tanvex BioPharma, Inc. from September 5, 2024.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Stephen Lam	Chief Executive Officer	less than a year	geen gegevens	geen gegevens
Allen Chao	Founder & Honorary Chairman	no data	NT$111.00k	0.87% NT$ 88.9m
Wen Yeh	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Val Chen	VP of Finance Director of Ops. Mgmt.	no data	geen gegevens	geen gegevens
James Williamson	Accounting Officer	less than a year	geen gegevens	geen gegevens
Zheng Xia	Chief Technology Officer	9.9yrs	geen gegevens	geen gegevens
Linda Grillo	Director of Sales & Marketing	no data	geen gegevens	geen gegevens
Hsun-Chiang Hsieh	Secretary	no data	geen gegevens	geen gegevens

0.9yrs

Gemiddelde duur

Ervaren management: Het managementteam van 6541 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Allen Chao	Founder & Honorary Chairman	11.4yrs	NT$111.00k	0.87% NT$ 88.9m
David Hsia	Director	9.5yrs	geen gegevens	0.50% NT$ 50.7m
Lin-Cheng Chen	Chairman	less than a year	NT$5.00k	geen gegevens
Chi-Chuan Chen	Director	11.1yrs	NT$25.00k	0.010% NT$ 1.0m
Tamon Tseng	Director	11.1yrs	NT$25.00k	geen gegevens
Jin-Pau Tsai	Independent Director	9.5yrs	NT$682.00k	geen gegevens
Tay-Chang Wang	Independent Director	3.3yrs	NT$687.00k	geen gegevens
Jang-Yang Chang	Independent Director	2.4yrs	NT$570.00k	geen gegevens
Shang-Hsien Hsieh	Independent Director	less than a year	geen gegevens	geen gegevens
Chi-feng Chang	Independent Director	less than a year	geen gegevens	geen gegevens
Chun-Yen Chang	Independent Director	2.4yrs	NT$622.00k	geen gegevens

3.3yrs

Gemiddelde duur

72yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 6541 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Tanvex BioPharma Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

High number of new directors

Tanvex BioPharma, Inc. Announces Change of CEO

High number of new directors

Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024

Tanvex BioPharma, Inc., Annual General Meeting, Jun 19, 2024

Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer

Recent updates

Tanvex BioPharma, Inc. to Report Q3, 2024 Results on Nov 08, 2024

High number of new directors

Tanvex BioPharma, Inc. Announces Change of CEO

Second quarter 2024 earnings released: NT$2.31 loss per share (vs NT$3.89 loss in 2Q 2023)

Tanvex BioPharma, Inc. (TWSE:6541) agreed to acquire Bora Biologics Co., Ltd. from Bora Pharmaceuticals Co., LTD. (TWSE:6472) and others for TWD 4.52 billion.

Does Tanvex BioPharma (TWSE:6541) Have A Healthy Balance Sheet?

Tanvex BioPharma, Inc. to Report Q2, 2024 Results on Aug 09, 2024

High number of new directors

Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024

First quarter 2024 earnings released: NT$3.12 loss per share (vs NT$5.17 loss in 1Q 2023)

Tanvex BioPharma, Inc. to Report Q1, 2024 Results on May 07, 2024

Tanvex BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of TWD 1.44 billion.

Tanvex BioPharma, Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: NT$16.58 loss per share (vs NT$13.96 loss in FY 2022)

New major risk - Financial position

Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer

Tanvex BioPharma, Inc. Announces the Resignation of Ken Huang as Accounting Officer

Tanvex BioPharma, Inc. Announces Change of Chairman

Tanvex BioPharma, Inc. Announces Change of Corporate Governance Officer

Tanvex BioPharma, Inc. Announces the Resignation of Stacey Tsai as Acting Spokesperson and Corporate Governance Officer

Tanvex BioPharma, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Second quarter 2023 earnings released: NT$3.89 loss per share (vs NT$3.63 loss in 2Q 2022)

New minor risk - Shareholder dilution

Tanvex BioPharma, Inc. announced that it expects to receive TWD 220 million in funding

Less than half of directors are independent

Tanvex BioPharma, Inc. announced a financing transaction

Tanvex BioPharma, Inc. Appoints Jang-Yang Chang as Independent Director

Less than half of directors are independent

Tanvex BioPharma, Inc., Annual General Meeting, Jun 17, 2022

Tanvex BioPharma, Inc. Announces the Appointment of K. H. Lin as CFO and Accounting Officer, Effective from February 18, 2022

Price target decreased to NT$53.00

Price target increased to NT$67.00

Is Tanvex BioPharma (TPE:6541) Using Too Much Debt?

Tanvex BioPharma, Inc. Enters into A License Agreement with Amgen

New 90-day high: NT$44.95

Are Institutions Heavily Invested In Tanvex BioPharma, Inc.'s (TPE:6541) Shares?

New 90-day low: NT$36.55

New 90-day low: NT$37.15

Does Tanvex BioPharma (TPE:6541) Have A Healthy Balance Sheet?

New 90-day high: NT$45.95

Earnings miss expectations

New 90-day low - NT$37.00

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd